KEGG DISEASE: Ovarian cancer

DISEASE: Ovarian cancer

Entry

H00027                      Disease

Name

Ovarian cancer

Description

Ovarian cancer is the sixth most common cancer and the fifth leading cause of cancer-related death among women in developed countries. Approximately 90% of human ovarian cancer arises within the ovarian surface epithelium (OSE), with the rest originating from granulosa cells or, rarely, stroma or germ cells. Ovarian epithelial tumors are divided into mucinous, serous, endometrioid, and clear cell subtypes. Approximately 10% of ovarian cancers arise in women who have inherited mutations in cancer susceptibility genes (BRCA1 or BRCA2). The vast majority of ovarian cancers are sporadic, resulting from the accumulation of genetic damage over a lifetime. Several specific genes involved in ovarian carcinogenesis have been identified, including the p53 tumor suppressor gene and ERBB2 and PIK3CA oncogenes.

Category

Cancer

Brite

Human diseases in ICD-11 classification [BR:br08403]
02 Neoplasms
  Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues
   Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues
    Malignant neoplasms of female genital organs
     2C73  Malignant neoplasms of ovary
      H00027  Ovarian cancer
Tumor markers [br08442.html]
H00027
Cancer-associated carbohydrates [br08441.html]
H00027

Pathway

hsa04151

PI3K-Akt signaling pathway

hsa04919

Thyroid hormone signaling pathway

Gene

BRCA1 (germline mutation / deletion) [HSA:672] [KO:K10605]
BRCA2 (germline mutation / deletion) [HSA:675] [KO:K08775]
MSH2 (germline mutation) [HSA:4436] [KO:K08735]
MLH1 (germline mutation) [HSA:4292] [KO:K08734]
ERBB2 (amplification / overexpression) [HSA:2064] [KO:K05083]
K-ras (mutation) [HSA:3845] [KO:K07827]
AKT2 (amplification) [HSA:208] [KO:K04456]
PIK3CA (amplification) [HSA:5290] [KO:K00922]
c-MYC (overexpression) [HSA:4609] [KO:K04377]
p53 (mutation / deletion, overexpression) [HSA:7157] [KO:K04451]
CTNNB1 [HSA:1499] [KO:K02105]
PRKN [HSA:5071] [KO:K04556]
OPCML [HSA:4978] [KO:K06773]
AKT1 [HSA:207] [KO:K04456]
CDH1 [HSA:999] [KO:K05689]

Drug

Cyclophosphamide [DR:D00287]
Melphalan [DR:D00369]
Thiotepa [DR:D00583]
Gemcitabine hydrochloride [DR:D01155]
Paclitaxel [DR:D00491]
Topotecan hydrochloride [DR:D02168]
Doxorubicin hydrochloride [DR:D01275]
Bevacizumab [DR:D06409]
Mirvetuximab soravtansine [DR:D10954] (folate receptor alpha positive)
Cisplatin [DR:D00275]
Carboplatin [DR:D01363]
Olaparib [DR:D09730] (HRD-positive)
Niraparib tosilate hydrate [DR:D11895] (BRCA-mutated)
Rucaparib camsylate [DR:D10982] (BRCA-mutated)
Altretamine [DR:D02841]

Other DBs

ICD-11:

ICD-10:

MeSH:

OMIM:

Reference

PMID:15111296

Authors

Shih IeM, Kurman RJ.

Title

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Journal

Am J Pathol 164:1511-8 (2004)
DOI:10.1016/S0002-9440(10)63708-X

Reference

PMID:12886939

Authors

Katabuchi H, Okamura H.

Title

Cell biology of human ovarian surface epithelial cells and ovarian carcinogenesis.

Journal

Med Electron Microsc 36:74-86 (2003)
DOI:10.1007/s00795-002-0196-6

Reference

PMID:12413930

Authors

Wenham RM, Lancaster JM, Berchuck A.

Title

Molecular aspects of ovarian cancer.

Journal

Best Pract Res Clin Obstet Gynaecol 16:483-97 (2002)
DOI:10.1053/beog.2002.0298

Reference

PMID:10417756

Authors

Wright K, Wilson P, Morland S, Campbell I, Walsh M, Hurst T, Ward B, Cummings M, Chenevix-Trench G

Title

beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours.

Journal

Int J Cancer 82:625-9 (1999)
DOI:10.1002/(sici)1097-0215(19990827)82:5<625::aid-ijc1>3.0.co;2-2

Reference

PMID:14614460

Authors

Denison SR, Wang F, Becker NA, Schule B, Kock N, Phillips LA, Klein C, Smith DI

Title

Alterations in the common fragile site gene Parkin in ovarian and other cancers.

Journal

Oncogene 22:8370-8 (2003)
DOI:10.1038/sj.onc.1207072

Reference

PMID:22585860

Authors

McKie AB, Vaughan S, Zanini E, Okon IS, Louis L, de Sousa C, Greene MI, Wang Q, Agarwal R, Shaposhnikov D, Wong JL, Gungor H, Janczar S, El-Bahrawy M, Lam EW, Chayen NE, Gabra H

Title

The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.

Journal

Cancer Discov 2:156-71 (2012)
DOI:10.1158/2159-8290.CD-11-0256

Reference

PMID:17611497

Authors

Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE

Title

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.

Journal

Nature 448:439-44 (2007)
DOI:10.1038/nature05933

Reference

PMID:18026186

Authors

Blechschmidt K, Sassen S, Schmalfeldt B, Schuster T, Hofler H, Becker KF

Title

The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients.

Journal

Br J Cancer 98:489-95 (2008)
DOI:10.1038/sj.bjc.6604115

» Japanese version

All links

Ontology (2)   
   KEGG BRITE (2)   
Disease (1)   
   OMIM (1)   
Drug (27)   
   KEGG DRUG (27)   
Gene (29)   
   KEGG ORTHOLOGY (14)   
   KEGG GENES (15)   
Literature (8)   
   PubMed (8)   
All databases (67)   

Download RDF

DBGET integrated database retrieval system